Alaa Abuquta

Dubai, DU, United Arab Emirates

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Al Kuwait Hospital Dubai, Emirates Health Services 1st Research Week 2025: Research Abstracts of Clinical and Scientific Advances.

Al Kuwait Hospital Dubai, Emirates Health Services 1st Research Week 2025: Research Abstracts of Clinical and Scientific Advances.

Journal: Saudi medical journal

Published: July 14, 2026

Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated Adults.

Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated Adults.

Journal: Vaccines

Published: August 16, 2024

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.

Journal: Expert review of vaccines

Published: March 26, 2024

Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men.

Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men.

Journal: Nature communications

Published: January 08, 2024

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine.

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine.

Journal: Cell discovery

Published: August 05, 2023

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.

Journal: EClinicalMedicine

Published: May 11, 2023

Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open-label, and single-arm Phase 1 study.

Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open-label, and single-arm Phase 1 study.

Journal: Clinical and translational medicine

Published: March 14, 2023

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men.

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men.

Journal: Nature communications

Published: February 01, 2023

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial.

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial.

Journal: The Journal of infection

Published: November 26, 2022

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.

Journal: EBioMedicine

Published: September 23, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026